pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer

M. Correale; I. Abbate; A. Paradiso; F. Schittulli; C. D. Dragone; T. Tedone; G. Gargano; A. M. Catino; M. D. Musci; M. De Lena

doi:10.1007/BF03033869

pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer

M. Correale, I. Abbate, A. Paradiso, F. Schittulli, C. D. Dragone, T. Tedone, G. Gargano, A. M. Catino, M. D. Musci, M. De Lena

Research output: Contribution to journal › Article › peer-review

Abstract

Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

Original language	English
Pages (from-to)	101-110
Number of pages	10
Journal	Cell Biophysics
Volume	22
Issue number	1-3
DOIs	https://doi.org/10.1007/BF03033869
Publication status	Published - Jan 1993

Keywords

Breast cancer
hormone sensitivity
pS2

ASJC Scopus subject areas

Cell Biology
Biophysics

Access to Document

10.1007/BF03033869

Cite this

@article{71f8d79198bf4101a6e091dfe7e73627,

title = "pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer",

abstract = "Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.",

keywords = "Breast cancer, hormone sensitivity, pS2",

author = "M. Correale and I. Abbate and A. Paradiso and F. Schittulli and Dragone, {C. D.} and T. Tedone and G. Gargano and Catino, {A. M.} and Musci, {M. D.} and {De Lena}, M.",

year = "1993",

month = jan,

doi = "10.1007/BF03033869",

language = "English",

volume = "22",

pages = "101--110",

journal = "Cell Biochemistry and Biophysics",

issn = "1085-9195",

publisher = "Humana Press",

number = "1-3",

}

TY - JOUR

T1 - pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer

AU - Correale, M.

AU - Abbate, I.

AU - Paradiso, A.

AU - Schittulli, F.

AU - Dragone, C. D.

AU - Tedone, T.

AU - Gargano, G.

AU - Catino, A. M.

AU - Musci, M. D.

AU - De Lena, M.

PY - 1993/1

Y1 - 1993/1

N2 - Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

AB - Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

KW - Breast cancer

KW - hormone sensitivity

KW - pS2

UR - http://www.scopus.com/inward/record.url?scp=0027538975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027538975&partnerID=8YFLogxK

U2 - 10.1007/BF03033869

DO - 10.1007/BF03033869

M3 - Article

C2 - 7889536

AN - SCOPUS:0027538975

VL - 22

SP - 101

EP - 110

JO - Cell Biochemistry and Biophysics

JF - Cell Biochemistry and Biophysics

SN - 1085-9195

IS - 1-3

ER -

pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this